Condition: Malignant Peritoneal Mesothelioma, Advanced · Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
This description comes directly from the study's public registry record.
Yongkun Sun · 13141276041 · hsunyk@cicams.ac.cn
Yuting Fang · 13700902492 · fangyuting502@163.com
Always discuss trial participation with your own doctor first.
| Cancer Institute and Hospital,Chinese Academy of Medical Sciences | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06543069